| Literature DB >> 24598725 |
Jennifer Haas1, Andrew Franklin2, Matthew Houser2, David Maraldo3, Mark Mikola2, Roberto Ortiz2, Elizabeth Sullivan2, José M Otero3.
Abstract
This case study provides an example of how Quality by Design (QbD) principles were applied to accelerate process development to manufacture a vaccine candidate at commercial scale. By leveraging an existing manufacturing platform process, a risk assessment was used to differentiate process parameters that could be defined using a combination of scientific and historical manufacturing knowledge from those that merited additional process characterization by experimentation. Select parameters, and their interactions, were evaluated by a Design of Experiment (DoE) series. This systematic approach required less time and fewer resources and resulted in the definition of a reliable and robust manufacturing process that meets regulatory requirements.Keywords: FMEA; Process development; Quality by Design; Vaccines
Mesh:
Substances:
Year: 2014 PMID: 24598725 DOI: 10.1016/j.vaccine.2014.02.028
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641